BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Wei L, Wang FS, Zhang MX, Jia JD, Yakovlev AA, Xie W, Burnevich E, Niu JQ, Jung YJ, Jiang XJ, Xu M, Chen XY, Xie Q, Li J, Hou JL, Tang H, Dou XG, Gandhi Y, Hu WH, McPhee F, Noviello S, Treitel M, Mo L, Deng J. Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection. World J Gastroenterol 2018; 24(12): 1361-1372 [PMID: 29599611 DOI: 10.3748/wjg.v24.i12.1361]
URL: https://www.wjgnet.com/1007-9327/full/v24/i12/1361.htm
Number Citing Articles
1
Qing Xie, Jian-Wei Xuan, Hong Tang, Xiao-Guang Ye, Peng Xu, I-Heng Lee, Shan-Lian Hu. Hepatitis C virus cure with direct acting antivirals: Clinical, economic, societal and patient value for ChinaWorld Journal of Hepatology 2019; 11(5): 421-441 doi: 10.4254/wjh.v11.i5.421
2
Ke-Qin Hu, Wei Cui, Susan D Rouster, Kenneth E Sherman. Hepatitis C virus antigens enzyme immunoassay for one-step diagnosis of hepatitis C virus coinfection in human immunodeficiency virus infected individualsWorld Journal of Hepatology 2019; 11(5): 442-449 doi: 10.4254/wjh.v11.i5.442
3
Krystyna Dobrowolska, Michał Brzdęk, Piotr Rzymski, Robert Flisiak, Małgorzata Pawłowska, Jakub Janczura, Kinga Brzdęk, Dorota Zarębska-Michaluk. Revolutionizing hepatitis C treatment: next-gen direct-acting antiviralsExpert Opinion on Pharmacotherapy 2024; 25(7): 833 doi: 10.1080/14656566.2024.2358139
4
Wen Chen, Thomas Ward, Mai Ping Tan, Jing Yan, Peter Feng Wang, Gail D Wygant, Jason Gordon. Daclatasvir combined with asunaprevir is a cost-effective and cost-saving treatment for hepatitis C infection in ChinaJournal of Comparative Effectiveness Research 2018; 7(8): 785 doi: 10.2217/cer-2018-0005
5
Huiying Rao, Xingxiang Yang, Youwen Tan, Qin Ning, Daokun Yang, Jiefei Wang, Yongfeng Yang, Sujun Zheng, Dongliang Yang, Jinlin Hou, Qing Xie, Caiyan Zhao, Lunli Zhang, Xiaorong Mao, Tong Sun, Lang Bai, Fuchun Zhang, Jinglan Jin, Yingren Zhao, Maorong Wang, Wen Xie, Yingjie Ma, Jun Quan, Xuebing Yan, Ping An, Feng Lin, Jidong Jia, Xiaoxuan Hu, Zuojiong Gong, Jie Wu, Yongping Chen, Zhansheng Jia, Minghua Lin, Guiqiang Wang, Yueyong Zhu, Yingjun Zhang, Hongming Xie, Lin Luo, Qingyun Ren, Rui Huang, Lai Wei. Efficacy and Safety of All-oral Emitasvir and Sofosbuvir in Patients with Genotype 1b HCV Infections without CirrhosisJournal of Clinical and Translational Hepatology 2020; 8(4): 1 doi: 10.14218/JCTH.2020.00031
6
Michael Murray. The Role of CYPs and Transporters in the Biotransformation and Transport of the Anti-hepatitis C Antiviral Agents Asunaprevir, Daclatasvir, and Beclabuvir: Impact of Liver Disease, Race and Drug-drug Interactions on Safety and EfficacyCurrent Drug Metabolism 2024; 25(2): 96 doi: 10.2174/0113892002288832240213095622
7
Lanlan Xiao, Xiaoxin Wu, Fen Zhang, Jie Wang, Xiaowei Xu, Lanjuan Li. Changes of inflammatory cytokines/chemokines during ravidasvir plus ritonavir‐boosted danoprevir and ribavirin therapy for patients with genotype 1b hepatitis C infectionJournal of Medical Virology 2020; 92(12): 3516 doi: 10.1002/jmv.26161
8
Luis A Bernal, Varun Soti. Hepatitis C Virus: Insights Into Its History, Treatment, Challenges, and Future DirectionsCureus 2023;  doi: 10.7759/cureus.43924